People with psoriasis who take an immune-modulating treatment
are no more likely to get serious infections than people taking standard therapies, according to a recent study published in the Journal
of investigative dermatology
. This study used a large database of people with psoriasis from the UK and Ireland. It compared serious
infection risk of the biological therapies – etanercept, adalimumab or ustekinumab (n=5,617) – with non-biological oral therapies (n=3,421). After
accounting for factors such as other illnesses, it found none of the biological therapies studied had a higher risk of infection compared to non-biological
therapies or compared to each other.
Read NIHR review